Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceftazidime + avibactam (Suncure Lifescience)
- Development stage
- Phase 2
- Lead developer
- Suncure Lifescience
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Bactodac 2.5** is a Suncure Lifescience branded fixed-dose antibacterial injection containing ceftazidime 2 g and avibactam 0.5 g. Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell-wall synthesis through penicillin-binding proteins, while avibactam inhibits bacterial beta-lactamases that would otherwise degrade ceftazidime. The combination is used for severe Gram-negative bacterial infections, including infections of the lungs, urinary tract, and abdomen. ([suncurelife.com](https://suncurelife.com/Key-Product-Detail/Bactodac%202_5.html))
- Brand names
- AvycazBactodacZavicefta
- Other names
- CAZ-AVIceftazidime + avibactamceftazidime-avibactamceftazidime/avibactam
02
Targets
PBP (Penicillin-binding protein family)Neuraminidaseβ-lactamase
Beyond the preview
Go deeper on ceftazidime + avibactam (Suncure Lifescience).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceftazidime + avibactam (Suncure Lifescience).